ABBV vs PFE Comparison: AI Score, Valuation, Performance and Upside
Compare AbbVie's successful Humira patent-cliff replacement strategy against Pfizer's lower valuation and ongoing post-pandemic revenue normalization.
Use this AbbVie vs Pfizer comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
ABBV holds the edge across 4 of 5 key metrics in this comparison. ABBV has delivered stronger 1-year price return (+20.88% vs +14.94%), though PFE has the better forward P/E setup (9.83x vs 15.79x for ABBV). ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+7.85%) than for PFE (+0.55%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | ABBV | PFE |
|---|---|---|
| AI scorei | 53.2 | 39.3 |
| AI ranki | #353 | #1256 |
| Latest closei | $263.04 | $27.55 |
| 1M returni | +5.44% | +2.84% |
| 6M returni | +19.69% | +0.36% |
| 1Y returni | +20.88% | +14.94% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | PFE |
|---|---|---|
| 1Y ago | $12.16K (+21.6%) started 2025-09-16 | $11.53K (+15.3%) started 2025-09-16 |
| 5Y ago | $32.94K (+229.4%) started 2021-09-17 | $9.14K (-8.6%) started 2021-09-17 |
| 10Y ago | $94.76K (+847.6%) started 2016-09-19 | $19.49K (+94.9%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | PFE |
|---|---|---|
| Market capi | $454.36B | $162.16B |
| Trailing P/Ei | 72.43 | 37.43 |
| Forward P/Ei | 15.79 | 9.83 |
| Price/Salesi | 5.85 | 2.13 |
| EV/Revenuei | 8.06 | 3.36 |
| Analyst targeti | $277.31 | $28.61 |
| Target upsidei | +7.85% | +0.55% |
| Metric | ABBV | PFE |
|---|---|---|
| Revenue growthi | 10.20% | 2.60% |
| Earnings growthi | 290.40% | -10.10% |
| EPS growthi | +290.40% | -10.10% |
| FCF margini | +26.20% | +19.60% |
| Operating margini | 40.03% | 27.88% |
| Profit margini | 9.80% | 6.80% |
| ROIC proxyi | 6225.00% | 5.01% |
| Return on equityi | 6225.00% | 5.01% |
| Dividend yieldi | 2.69% | 6.05% |
| Payout ratioi | 190.40% | 226.32% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.28 | 0.30 |
| Debt/equityi | 4789.60 | 74.25 |
| Current ratioi | 0.81 | 1.27 |
| Quick ratioi | 0.49 | 0.85 |
Over the past year, ABBV and PFE have moved weakly in the same direction (correlation of 0.40), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | PFE |
|---|---|---|---|
| 1Y | Growthi | +21.63% | +15.27% |
| CAGRi | +21.68% | +15.30% | |
| Volatilityi | 26.51% | 23.60% | |
| Sharpe ratioi | 0.70 | 0.53 | |
| Sortino ratioi | 1.08 | 0.83 | |
| Max drawdowni | 19.23% | 17.09% | |
| Current drawdowni | 1.10% | 5.07% | |
| Avg drawdowni | 7.66% | 6.68% | |
| Ulcer Indexi | 9.00% | 7.90% | |
| Max daily dropi | 5.20% | 3.43% | |
| Max wkly dropi | 8.49% | 9.46% | |
| 5Y | Growthi | +182.09% | -24.87% |
| CAGRi | +23.06% | -5.56% | |
| Volatilityi | 23.39% | 25.41% | |
| Sharpe ratioi | 0.82 | -0.28 | |
| Sortino ratioi | 1.14 | -0.40 | |
| Max drawdowni | 21.92% | 58.96% | |
| Current drawdowni | 1.10% | 46.63% | |
| Avg drawdowni | 8.02% | 38.10% | |
| Ulcer Indexi | 9.98% | 41.44% | |
| Max daily dropi | 12.57% | 6.72% | |
| Max wkly dropi | 17.30% | 11.19% | |
| 10Y | Growthi | +506.11% | +24.86% |
| CAGRi | +19.76% | +2.25% | |
| Volatilityi | 26.03% | 24.09% | |
| Sharpe ratioi | 0.65 | 0.03 | |
| Sortino ratioi | 0.91 | 0.04 | |
| Max drawdowni | 45.09% | 58.96% | |
| Current drawdowni | 1.10% | 46.63% | |
| Avg drawdowni | 11.55% | 23.43% | |
| Ulcer Indexi | 15.57% | 30.32% | |
| Max daily dropi | 16.25% | 7.73% | |
| Max wkly dropi | 19.39% | 15.34% |
| Category | ABBV | PFE |
|---|---|---|
| Company | ABBV | PFE |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. | Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.